Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueFCF MarginGross MarginInterest Coverage RatioInventory AverageNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

CureVac (CVAC) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for CureVac (CVAC) over the last 7 years, with Q3 2025 value amounting to 504.72%.

  • CureVac's EBITDA Margin rose 4362500.0% to 504.72% in Q3 2025 from the same period last year, while for Sep 2025 it was 487.12%, marking a year-over-year increase of 4146800.0%. This contributed to the annual value of 33.2% for FY2024, which is 5432800.0% up from last year.
  • Per CureVac's latest filing, its EBITDA Margin stood at 504.72% for Q3 2025, which was up 4362500.0% from 4802.49% recorded in Q2 2025.
  • In the past 5 years, CureVac's EBITDA Margin registered a high of 5845.13% during Q1 2025, and its lowest value of 1038.46% during Q4 2022.
  • Moreover, its 5-year median value for EBITDA Margin was 491.66% (2021), whereas its average is 791.01%.
  • As far as peak fluctuations go, CureVac's EBITDA Margin plummeted by -10723500bps in 2022, and later skyrocketed by 52744600bps in 2025.
  • Quarter analysis of 5 years shows CureVac's EBITDA Margin stood at 13.35% in 2021, then crashed by -7679bps to 1038.46% in 2022, then soared by 63bps to 389.38% in 2023, then rose by 22bps to 302.07% in 2024, then soared by 267bps to 504.72% in 2025.
  • Its EBITDA Margin stands at 504.72% for Q3 2025, versus 4802.49% for Q2 2025 and 5845.13% for Q1 2025.